Boosting effect of high-dose influenza vaccination on innate immunity among elderly: a randomized-control trial

ABSTRACT: This study is a phase IV, randomized (1:1 ratio, blocks of various size, electronic allocation), open-label, active-controlled, multi-center trial enrolling adults aged sixty-five years or older to evaluate the different mechanisms of the immunological action of QIV-HD (Efluelda®) compared to QIV-SD (InfluvacTetra®). For transcriptomic analysis, 2.5 ml whole blood was collected in PAXgene tubes (Qiagen) from each subject before vaccination (D-7and D0) and 24 hours after (D1). Total RNA was extracted from blood according to the handbook of the PAXgene Blood RNA Kit. Purity and integrity of the RNA was assessed on the Agilent 2100 Bioanalyzer with the RNA 6000 Nano LabChip reagent set. One V2 sample (#02-066-FB) of QIV-SD group without good RNA quantity was removed for transcriptomic analy

INSTRUMENT(S): PAXgene Blood RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland)., Applied BiosystemsTM GeneChipTM Whole Transcript (WT) PLUS Reagent Kit User Guide (Thermo Fisher Scientific, Waltham, MA, USA)., Applied BiosystemsTM GeneChipTM Clariom S human arrays

ORGANISM(S): Homo sapiens

SUBMITTER:  

PROVIDER: E-MTAB-14109 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress